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Background
Celiac disease (CD) is defined as a condition that affects 
the morphology of the mucosa of the small intestines, 
and it is improved if the patient consumes a gluten-free 
diet and relapses if gluten is reintroduced in the diet (1). 
The prevalence of CD is high in the general Iranian popu-
lation (1 in 166) (2), and the disease is currently consid-
ered the result of a complex interplay between inherent 
and environmental factors. The typical or classical form 
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of CD is due to the interaction between gliadin and anti-
bodies to tissue transglutaminase (tTG), and it results in 
the flattening of the villi in the small intestinal mucosa 
(3). Although CD is known to affect the small intestine, it 
is a multisystem disorder and can involve other organs 
such as the skin, thyroid, pancreas, heart, liver, joints, 
muscles, bones, the reproductive system, the central and 
peripheral nervous systems (4-13).
The occurrence of liver impairment in CD is well estab-
lished and must be regarded as one of the various extraint-
estinal presentations of gluten-sensitive enteropathy (14-
17). The association between CD and liver manifestations 
was first reported in 1977 (14). In this study, 30 of 74 adults 
newly diagnosed with CD had elevated levels of serum 
aminotransferase enzymes, which normalized after ad-
herence to a gluten-free diet in most cases. In this study,   Copyright  c 2011, BRCGL, Published by Kowsar M.P.Co  All right reserved.Hepat Mon. 2011;11(5):333-341
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(NAFLD), nonalcoholic steatohepatitis (NASH), hepatitis 
C virus (HCV)-related liver disease, and hepatitis B virus 
(HBV)-related liver disease are very common in the gen-
eral Iranian population (23-25), and their incidence in 
patients with CD is likely a coincidence rather than a 
true correlation. Recently, 2 different types of liver injury, 
namely cryptogenic liver disorder (mild or severe type) 
and autoimmune liver disorder, have been found to be 
strongly related to CD. Cryptogenic liver disorder can be 
distinguished from autoimmune liver disorder on the 
basis of its positive response to gluten-free diet (GFD).
Cryptogenic liver disorders 
1. Mild liver damage (gluten-induced hepatitis)
The first report of gluten-induced hepatitis, published 
in The Journal of Pediatric Gastroenterology and Nutri-
tion in 1986, was the case of a young girl with persistent 
cryptogenic elevation of serum aminotransferase levels 
and mild inflammation of the portal tract (26). A diag-
nosis of CD, suggested in this case by a high titer of anti-
reticulin antibody, was confirmed by duodenal biopsy. 
Bardella et al. performed a similar study and found that 
13 (9%) of 140 screened patients tested positive for anti-
gliadin antibody (AGA) and anti-endomysial antibody 
(EMA). The relative risk of CD in these patients (18.6%) 
was significantly greater than that in the general popu-
lation. Antibodies associated with CD disappeared after 
12 months of consuming a GFD, but liver enzyme levels 
normalized in only 1 patient (27). This form of CD was 
once called “gluten-induced hepatitis” (28) and is now 
suggested to be celiac hepatitis, which is characterized 
by mild periportal inflammation with Kupffer cell hyper-
plasia, mononuclear cell infiltration, absence of any clin-
ical features suggesting chronic liver disease, absence of 
hypergammaglobulinemia, absence of serum autoanti-
bodies, presence of mild lobular and portal tract inflam-
mation, and absence of hepatomegaly, splenomegaly, or 
both; this form is reversible if a GFD is consumed. In the 
majority of patients with hypertransaminasemia at diag-
nosis, liver enzymes returned to normal levels within 6 
months of starting a strict GFD (29) and in almost all cas-
es, returned to normal levels within 12 months of gluten 
withdrawal. Occasionally, hypertransaminasemia might 
be the only sign of CD, which is manifested without any 
gastrointestinal (GI) symptoms. The results of a study by 
Volta et al. showed that 9% of patients with increased lev-
els of transaminase of unknown origin had asymptom-
atic CD (28). Furthermore, evaluation of 110 patients with 
cryptogenic hypertransaminasemia showed that 10% of 
patients with elevated transaminase levels were also pos-
itive for silent CD (29).
On the basis of the high prevalence of CD (9.3%) in pa-
tients with unexplained increases in serum transami-
nase levels, Bardella, et al. confirmed that cryptogenic 
hypertransaminasemia could be a possible extraintes-
tinal sign of CD (30). Furthermore, investigators found 
that children with unknown causes of hypertransami-
nasemia had asymptomatic CD. By consuming a GFD, pa-
tients experienced rapid improvements in both hepatic 
and intestinal biochemical/histologic signs, thus con-
firming that the liver damage was gluten-dependent (31). 
In a few studies, it was reported that some patients on a 
GFD for 12 months newly experienced increases in their 
liver enzyme levels, and this increase was probably be-
cause of the high quantities of lipids contained in some 
gluten-free foods (31, 32).
2. Severe liver damage
Severe histological diseases, including chronic hepati-
tis, severe fibrosis, and cirrhosis have been reported in 
adults and children (14, 25, 31). CD was detected in some 
patients with severe liver damage of unknown origin, 
and surprisingly, clinical improvement in the liver con-
dition was noted when the patients consumed a GFD 
(33-35). The prevalence of CD in patients with chronic 
liver disease is higher than in the general population. 
Lindgren et al. reported that in 327 patients with chronic 
liver disease, the prevalence of CD was 1.5%, which is 15 
times higher than that in the general population (36). 
In a Finnish study, CD was reported in 4 adult patients 
signs of reactive hepatitis were noted in 5 of 13 patients, 
and different types of histologic lesions were found in 7 
patients. Since the 1990s, a close association between CD 
and autoimmune liver disease has been clearly indicated 
in relevant studies (18-21). 
Searches were performed in PubMed and SID (for Per-
sian papers) for articles published in English- and Per-
sian-language journals from 1977 to November 2010; the 
following keywords were used alone or in combination: 
“celiac disease,” “liver disorders,” “liver abnormality,” 
“liver injury,” “hepatitis,” “anti-tTG,” “anti-endomysial,” 
and “cholangitis.” The aim of this review is to discuss the 
major forms of liver abnormalities associated with CD 
and to evaluate the prognosis of these abnormalities.
Liver Dysfunction related to CD
Patients with CD have damaged gut mucosa, which 
can lead to malabsorption and increased permeability. A 
wide variety of liver injuries may occur in CD (22), and 
the principal conditions are listed in Table 1. 
Conditions such as nonalcoholic fatty liver disease 
Cryptogenic 
liver disorders
High liver enzymes due to gluten in-
duced reactive hepatitis
Autoimmune 
liver disease
 Autoimmune hepatitis (AIH)
 Autoimmune overlap syndrome
 Primary sclerosing cholangitis (PSC)
 Primary biliary cirrhosis (PBC)
 Nonalcoholic fatty liver disease (NAFLD)
 Nonalcoholic steatohepatitis (NASH)
 Hepatitis C virus (HCV)-related liver 
disease
Table 1. Characterization of cryptogenic liver disorders related to CDHepat Mon. 2011;11(5):333-341
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(3 men and 1 woman) with severe liver disease, who 
were waiting for liver transplantation (33). Two of them 
had progressive hepatitis, congenital liver fibrosis, and 
massive hepatitis steatosis. Clinical symptoms, includ-
ing ascites and jaundice, improved in all patients after 
6 months of consuming a GFD. Of 185 Finnish patients 
who underwent transplantation, 8 (4.3%) were found to 
have CD; this rate is 4–10 times higher than that found 
in the general population (33). During the study for a 
transplant programin a 28-year-old woman with severe 
cryptogenic liver failure had a complete recovery of liver 
function after a few months of following a GFD (34).
3. Autoimmune liver diseases
3-1) Primary biliary cirrhosis
The relationship between CD and primary biliary cir-
rhosis (PBC) is well documented, and it was first reported 
by Logan, et al. in 1978 (37). Consequently, PBC patients 
have been extensively screened for CD. The reported 
prevalence of CD in PBC varies between 0 and 11%, and 
about 6% of individuals with CD may be affected by PBC 
(20, 38, 39). In a 12-year epidemiological study of a Brit-
ish population of 250,000, Kingham and Parker (38) ac-
cessed a large registry of patients with PBC and CD. They 
found that CD was identified in 4 of 67 (6%) patients with 
PBC and that 4 of 143 (3%) patients with CD were affect-
ed by PBC. In another study conducted in UK, in which 
4,732 CD patients were matched with 23,620 controls, 
the prevalence of PBC was found to be 0.17% in patients 
with CD versus 0.05% in controls (39). This trend was con-
firmed by 2 large population-based studies from Danish 
and Swedish cohorts (40). In these studies, EMA antibody 
tests were positive in 11% of PBC patients. The titer of mi-
tochondrial antibodies, which are markers of PBC, did 
not change after gluten removal. Various case reports on 
the association between CD and PBC have shown that a 
GFD induces a stable clinical and biochemical improve-
ment because of the normalization of intestinal absorp-
tion, but it does not seem to adjust the course of the liver 
disorder (41-49). However, some studies have shown that 
there is no association between CD and PBC (50, 51), but 
these studies tended to have small numbers of studied 
patients. In addition, numerous investigations have 
reported the positive effect of a GFD in primary biliary 
cirrhosis, thereby suggesting that all patients with PBC 
should be screened for CD (8, 13-20, 52-55).
3-2) Primary sclerosing cholangitis
No distinguishing autoantibody has been found in pa-
tients with primary sclerosing cholangitis (PSC). Using 
cholangiography as a diagnostic tool, the characteristics 
of the biliary lesion can be evaluated in biopsy tissue or 
the appearance of the intra- and extrahepatic biliary tree 
can be assessed (12). Several studies have found a positive 
correlation between PSC and CD; however, these studies 
involve small numbers of investigated patients, and also, 
surveillance bias has not been taken into account. This 
association was first suggested by Hay, et al. in 1988 (56), 
who described the cases of 3 PSC patients (confirmed by 
cholangiopancreatography retrograde endoscopy and 
liver biopsy) with steatorrhea as a severe form of malab-
sorption. Diarrhea was ameliorated after the diagnosis 
of CD and consumption of a GFD, but the course of PSC 
did not improve. In a recent study by Volta, et al. positive 
anti-EMA antibody was found in 1 of 61 patients with PSC, 
thus showing a prevalence of 1.6% for CD (20). The rela-
tionship between PSC and CD has not been extensively 
studied. In a study of 13,818 patients with CD and 66,584 
age- and sex-matched individuals from the general Swed-
ish population, the prevalence of PSC in CD patients was 
4.46%, a rate 4–8 times higher than that of the general 
population (57). In another survey, CD was found in 3% 
patients with PSC (58). 
Subsequently, the association between PSC and CD 
has been reported in several case reports (59-63). Liver 
enzyme levels in a 54-year-old man with CD, PSC, ulcer-
ative colitis, and Hashimoto’s thyroiditis were notice-
ably improved and finally normalized after 14 months 
of treatment with a GFD (64. A repeated liver biopsy 
showed marked improvement in liver histological char-
acteristics. In addition, in 2 studies, GFDs were reported 
to cause a significant improvement in hepatic histologi-
cal characteristics and cholestasis in 3 patients. The small 
number of studied cases does not allow the formation of 
a definite conclusion as to whether diet slows down the 
progression of this autoimmune liver disorder (57, 60). 
Further studies are needed to accurately determine the 
strength of the association between PSC and CD.
3-3) Autoimmune hepatitis
In the late 1970s, sporadic findings of CD in patients 
with autoimmune hepatitis (AIH) were reported for 
the first time (65-67). To evaluate the incidence of CD in 
patients with AIH, Volta, et al. studied the sera of 157 pa-
tients with type 1 AIH and 24 patients with type 2 AIH; CD 
was found in patients with both types of AIH and EMA an-
tibody was identified in 8 AIH patients (4%). CD was diag-
nosed in 5/8 patients who underwent a duodenal biopsy 
(19). However, the benefit of a GFD to the clinical course of 
AIH patients was not reported. This study was performed 
through cooperation between the Mayo Clinic (Roches-
ter, USA) and the University of Bologna (Italy). 
In another study, the prevalence of CD in patients with 
AIH was 6.4% (21). In a multicenter study in Italy, AIH oc-
curred in 1.1% of 909 children with CD and no case was 
found in either healthy populations or in patients with 
an alternate gastrointestinal ailment such as Crohn’s dis-
ease (68). Jacobsen, et al. studied 101 patients with CD (69) 
and detected chronic active hepatitis in 5 patients (2.3%) 
of 37 patients who underwent histologic evaluation. In 
addition, in a study by Novacek, et al. 3 (1.6%) of 178 pa-
tients with CD investigated for the presence of abnormal 
liver enzyme levels had documented AIH (70). In a study Hepat Mon. 2011;11(5):333-341
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done at King’s College, London, the prevalence of CD in 
96 children with AIH was 3.4%, which was significantly 
higher than expected (71). 
4. Autoimmune cholangitis 
An association between CD and autoimmune cholangi-
tis (AIC) has been described (72). Intestinal biopsies of pa-
tients with CD and AIC usually show either mild atrophy 
or an increased number of intraepithelial lymphocytes. 
In a 60-year-old woman who was evaluated for chronic 
elevations of serum liver biochemical parameters and 
unexplained iron deficiency anemia, a diagnosis of CD 
was made; subsequently, treatment with a GFD led to res-
olution of these abnormalities (73). These studies suggest 
that CD should be considered in all patients diagnosed 
with AIC, as a GFD may avoid the need for immunosup-
pressive therapy.
5. Other liver disorders in CD
5-1) Viral Hepatitis
Hepatitis B and C are prevalent in Iran (74-77). It is es-
timated that between 1.2% and 19.7% of the general pop-
ulation have hepatitis B surface antigen (HBs Ag) and 
0.12–0.89% have anti-hepatitis C virus antibodies, cor-
responding to 1.5–2.5 million HBV cases and 0.5 million 
chronic carriers of HCV (75, 76). In a study recently pub-
lished in Iran, 88 patients with chronic hepatitis B (CHB) 
were serologically tested for celiac autoantibodies, and 
9 seropositive patients underwent duodenal biopsy (78). 
Compared with the general population, the prevalence 
of celiac autoantibodies in CHB (11.3%) is relatively high, 
and most autoantibody-positive patients were asymp-
tomatic for CD.
Fifty-five percent of children and 68% of adults do not 
respond to standard vaccination regimens for hepatitis 
B virus. This lack of response to hepatitis B vaccine may 
be related to the genetic background of celiac patients, 
which seems to be linked to human leukocyte antigen 
(HLA) DQ2 (79, 80). Some authors have suggested that 
large follow-up studies with large sample sizes are neces-
sary to clarify how HBV infection affects the development 
of CD and to identify principal prevention strategies (81-
83). There is no convincing evidence that patients with 
viral hepatitis are at increased risk of developing CD (84, 
85), but an association between HCV infection and CD in 
adults has been reported. Indeed, HCV is suggested to be 
the most common liver disease associated with CD. Two 
hundred and fifty-nine patients who were consecutively 
evaluated with chronic hepatitis C (CHC) and 221 healthy 
volunteers underwent serologic screening for CD, and se-
ropositive patients underwent duodenal biopsy (86). The 
results of this study showed that the prevalence of CD in 
patients with CHC was 1.2%, while only 0.4% of healthy vol-
unteers had CD. In another study, the prevalence of anti-
bodies to tTG in 462 patients with CHC was higher than 
that in 1,350 healthy controls (87). A third study showed 
that the prevalence of CD in 534 patients affected by CHC 
was 1.3% (88).
A recent study of patients having both CD and HCV de-
scribed a well-defined route of transmission in most of 
these subjects, raising the hypothesis that the link be-
tween these diseases may be biased by the route of trans-
mission of hepatitis C infection (89). An association be-
tween HCV infection and CD has been hypothesized, but 
some studies show that there is no correlation between 
these 2 disorders. Thus, a clear association of CD and HCV 
is lacking. In a cross-sectional study, 827 multiparous 
pregnant women were serologically screened for CD and 
HCV antibodies by enzyme-linked immunosorbent assay 
(ELISA). Twenty-seven (3.26%) women had antibodies to 
tTG, but only 2 (0.24%) had antibodies to HCV and one of 
these also had antibodies to tTG. This result suggests that 
routine screening of HCV in CD patients is not efficient 
(90). Both interferon and ribavirin may enhance type 1 
helper T cell immune responses via signal transducers 
and activators of the transcription-dependent pathway, 
which subsequently induces the expression of inter-
feron (91-94). Cammarota, et al. reported 2 cases of CHC 
that displayed various features of CD during treatment 
with interferon. Symptoms and histological disorders 
improved after the interferon treatment was stopped 
and a GFD was consumed (92). Therefore, it is suitable 
to start treatment for HCV after CD diagnosis, and after 
a year of GFD, improvement of the intestinal disease can 
be achieved. Since HCV is a very common disorder and 
may be correlated to CD, the presence of undetected CD 
should be ruled out before starting treatment of inter-
feron in combination with ribavirin. Furthermore, CD 
should be considered in patients with unexplained diar-
rhea during or after interferon/ribavirin therapy.
Figure 1. Possible pathogenic mechanisms of liver abnormalities in CDHepat Mon. 2011;11(5):333-341
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5-2) NAFLD/NASH
Some conditions such as NAFLD and/or NASH are very 
common (up to 25%) in the general population (95), and 
its occurrence in patients with CD is likely to be a coinci-
dence rather than a true correlation (96). Some studies 
declare a clear association between CD and fatty liver 
and suggest performing serological screening and con-
tinually evaluating biochemical abnormalities for CD in 
NAFLD patients (18, 96). Bardella, et al. investigated 59 
patients with hypertransaminasemia and NAFLD, and 
38 (64%) were diagnosed with NASH by anti-EMA and 
anti-tTG antibodies. HLA-DQ typing and endoscopy were 
performed in 2 anti-EMA positive patients (3.4%) and 6 
anti-tTG positive patients (10%). On the basis of histologi-
cal findings, CD was confirmed only in 2 patients (3.4%) 
who were positive for both anti-EMA and anti-tTG. After 6 
months of a GFD, liver enzyme normalized in both cases 
(96). However, other studies do not recognize associa-
tions between CD and NAFLD (97). Nehra, et al. attempted 
to determine whether any relationship exists between 
NASH and CD by investigating the serology of 47 NASH 
patients, in whom NASH was confirmed by liver biopsy. 
Only one patient was EMA-positive, thus indicating that 
there is no association between positive CD serology and 
NASH (97). In contrast, Valera, et al. found positive CD 
markers in 3 of 38 NAFLD patients (7.9%), and histological 
evaluation showed Marsh I in 1 patient. The result of this 
study has indicated a high prevalence of positive tTG in 
patients with NAFLD (98). In an Italian study, the preva-
lence of silent CD in 59 consecutive patients with NAFLD 
was 3.4% (99), which suggested that screening with EMA 
is preferred to tTG antibodies since tTG positivity, in the 
absence of confirmatory anti-EMA antibodies, is not suf-
ficient to perform diagnostic endoscopy.
5-3) CD and hemochromatosis
CD and hemochromatosis are genetic disorders, but CD 
is paradoxically associated with iron deficiency anemia. 
Most published papers regarding these disorders togeth-
er are case reports (100). Singhal et al. reported the cases of 
2 patients who developed both CD and hereditary hemo-
chromatosis (101). In the first case, CD was diagnosed first 
and 8 years later, a routine blood screen showed elevated 
mean corpuscular and alanine transaminase (ALT) levels. 
Additional examinations showed transferrin saturation 
and increased levels of ferritin and iron. Genetic analy-
sis showed homozygosity for the C282Y gene mutation, 
which confirmed hemochromatosis. Liver biopsy showed 
Figure 2. Approach to the diagnosis of liver abnormalities in celiac disease
Celiac DiseaseHepat Mon. 2011;11(5):333-341
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an index consistent with hemochromatosis. The patient 
responded satisfactorily to venesections, with the serum 
ferritin levels presently maintained around 50 mg/L. The 
second case was that of a 54-year-old woman referred 
with abnormal ALT levels, but the rest of the liver profile 
and other biochemical tests were satisfactory. Screening 
tests for hepatitis B and C and the autoimmune profile 
were negative, but her serum ferritin level was notice-
ably raised. Heterozygosity for the H63D and C282Y mu-
tations was shown in a genetic study. The patient rapidly 
responded to venesection, but the level of ALT remained 
high. Because of increasing upper abdominal discom-
fort, she underwent endoscopy, and histological evalu-
ation confirmed CD. After 3 months of treatment with 
GFD, her liver disorders resolved completely and her ALT 
levels normalized (101).
Butterworth et al. investigated 145 CD patients and 187 
matched controls for the presence of HFE gene muta-
tions. The number of mutated C282Y and/or H63D genes 
were significantly higher in patients with CD (48.3%) 
compared to controls (32.6%). Nevertheless, none of the 
patients with CD showed a clinical presentation of hemo-
chromatosis. The results of this study showed that HFE 
gene mutations are more frequent in the CD population 
and may provide a survival benefit by ameliorating the 
iron deficiency seen in these patients (102). The present 
studies show that there is a rare association between CD 
and hemochromatosis, and therefore, more studies in 
this field are necessary to substantiate this observation.
Pathogenesis of liver dysfunction in CD 
The mechanism(s) of liver injury in CD is still unde-
fined. Intestinal permeability is increased in CD; this may 
enable the entry of toxins, antigens, and inflammatory 
materials to the portal circulation, and these mediators 
may have a role in the liver involvement seen in patients 
with CD (14, 28, 29, 56, 99). Although liver dysfunction oc-
curs not only in patients with CD but also in those with 
irritable bowel disease (IBD), cow milk enteropathy, and 
food allergies, patients with tropical sprue and increased 
intestinal permeability do not present with liver enzyme 
abnormalities as frequently as CD patients (56) (Figure 1). 
Most patients with liver injury associated with CD have 
no symptoms or signs of liver disorder at the time of 
diagnosis, although nonspecific symptoms such as mal-
aise and fatigue are common (14, 27, 28). The sensitivity 
and specificity of each sign is variable, but a combination 
of signs may otherwise raise the suspicion of CD. How-
ever, mild to moderate elevations in serum levels of as-
partate aminotransferase (AST) and/or ALT are the most 
common and often the only laboratory manifestations 
of liver injury in patients with CD. In a study of 98 con-
firmed CD patients with varied LFT, there was an increase 
in only ALT levels in 8 patients and AST levels in 5 of these 
8 patients (unpublished data) After adherence to a GFD 
for 6 months, elevations in serum aminotransferase lev-
els were normalized, thus explaining the correlation be-
tween liver injury and intestinal damage. 
Moreover, in view of the response to GFDs in hyper-
transaminasemia patients and abnormal ALP of suspect-
ed hepatic origin in CD patients, a liver biopsy may be 
useful. However, liver biopsy performance is dependent 
to some extent on factors such as patient age, associated 
co-morbid conditions, and the clinical significance of the 
liver test abnormality. Before interaction between envi-
ronmental and genetic factors lead to irretrievable liver 
injury, early recognition of CD would allow complete re-
covery from hepatic lesions. The following mechanisms 
have been suggested to have roles in establishing liver 
injury in CD: malabsorption and long-standing malnu-
trition, increased intestinal permeability, small intestine 
bacterial overgrowth, chronic intestinal inflammation, 
and a common genetic predisposition.
Furthermore, patients with CD who are exposed to glu-
ten during a gluten challenge are at higher risk to de-
velop autoimmune disease than those without further 
exposure (1, 103).
Genetic Correlation
Genetic predisposition has an important role in the de-
velopment of cryptogenic liver disorders in response to 
autoimmune hepatic injuries, and this might also con-
tribute to the association between CD and liver disease 
(57). Different studies reflect the importance of genetic 
factors in the pathogenesis of CD, which is associated 
with HLA class II molecules encoded by genes of the HLA 
complex on chromosome 6 (104). In this region, a large 
group of autoimmune diseases are linked to specific 
alleles or combinations of haplotypes (105). The main 
genetic marker of CD is the HLA-DQ2 (α1*0501, α1*0201) 
heterodimer, which is present in approximately 95% 
patients with CD, and the remaining patients have HLA-
DQ8 (α1*0301, β1*0302) (106). HLA-DQ2 is in strong link-
age with HLA-DR3, which is also the major HLA risk factor 
for AIH (107). In addition, AIH is associated with HLA-DR4 
and HLA-DR52 (108, 109). The same HLA class II molecule 
has an important role in the pathogenesis of PSC and 
CD. A shared immunogenetic predisposition to autoim-
munity may account for the association between these 
diseases (33, 110, 111). In a multicenter study in Europe, it 
was found that the frequencies of the HLA-DR3, HLA-DR13, 
HLA-DQ2, HLA-DQ8, and HLA-DQB1*0603 haplotypes were 
higher in patients with PSC compared with matched 
controls (112). In Finnish adults who had undergone liver 
transplantation, the frequency of HLA-DQ2 and HLA-DQ8 
in patients with PSC, autoimmune hepatitis, or acute 
liver failure was 56–75% compared with 39% in controls 
(33). Therefore, we suggest that there is a closer associa-
tion between CD and AIH/PSC than between CD and other 
liver disorders.
Conclusion
Liver abnormality may be one of the associated ex-Hepat Mon. 2011;11(5):333-341
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traintestinal manifestations of CD. However, because of 
the high frequency of CD in the general population, an 
accidental association between CD and the liver cannot 
be excluded. The liver damage in CD ranges from mild 
hepatic abnormalities to severe liver disease and may be 
seen in 15–55% of patients. The mechanisms underlying 
liver abnormalities in CD are not defined clearly. How-
ever, consumption of a GFD is an effective treatment for 
most patients with CD and liver disorders. After exclud-
ing other causes of liver disease and because of the high 
prevalence of liver disorders in CD, the levels of liver en-
zymes should be evaluated in all patients at the time of 
CD diagnosis (Figure 2).
In cases of cryptogenic hypertransaminasemia, 
transaminase levels will be normalized, and it is recom-
mended to re-check the liver enzyme levels after 6–12 
months of a strict GFD. Fatty liver also may be associated 
with CD, although it is unclear whether this is a cause, 
an effect, or a serendipitous association. The important 
point is that 10–20% of this group may show hyper-
transaminasemia again after 2 or more years of GFD be-
cause of metabolic changes in the liver owing to the high 
amount of lipids found in commercially available gluten-
free foods. For this reason, monitoring of transaminase 
levels once a year is recommended, especially in patients 
gaining weight. Since the association of CD with liver au-
toimmunity has been largely validated, the first step is 
requesting a serology test for CD in all cases of autoim-
mune liver disorders such as AIH, PBC, and PSC. Indeed, 
CD can be present in 3–7% of these patients.
EMA is more specific but slightly less sensitive than 
anti-tTG (113), and as is well known, false-positive results 
for anti-tTG are found in patients with liver and autoim-
mune disorders (114). Therefore, determination of the 
levels of EMA is preferred to that of anti-tTG in patients 
with cryptogenic and autoimmune liver disease. An ex-
ception is in children with inflammatory liver disease of 
unknown cause, where investigation for CD should be 
started by determining the anti-tTG levels. In conclusion, 
serological evaluations for CD should be part of the gen-
eral workup of patients with unexplained elevated liver 
enzyme levels when other causes of liver disease have 
been ruled out, and at the time of CD diagnosis, liver dys-
function should be concurrently evaluated.
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